Skip to main content
  • Olpasiran Reduces Lipoprotein(a) in Patients with Atherosclerotic CVD, Global Randomized Trial Reports

    The use of olpasiran therapy in patients with atherosclerotic cardiovascular disease significantly reduces lipoprotein(a) concentrations, according to new randomized trial results.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details